Pharmacology  ·  Sedative-Hypnotic Drugs

Clinical Management of Sedative-Hypnotic Toxicity

Overdose management, withdrawal severity, and tapering protocols

Abbreviations: CIWA-Ar = Clinical Institute Withdrawal Assessment for Alcohol (revised)  ·  GI = gastrointestinal  ·  QRS = QRS complex on ECG  ·  ICU = intensive care unit

Overdose: Three Drug Classes Compared
Benzodiazepine Overdose
Isolated: Rarely Fatal
  • Ceiling effect on GABA-A activation protects respiratory drive
  • Death almost always requires co-ingestant (opioid, alcohol, barbiturate)
  • Management: supportive care, airway monitoring
  • Flumazenil: use selectively (contraindicated if dependent or TCA co-ingestion)
Barbiturate Overdose
Potentially Fatal
  • No ceiling effect — profound respiratory depression possible
  • Supportive care: airway, ventilation, hemodynamic support
  • Urine alkalinization with sodium bicarbonate: enhances elimination of long-acting phenobarbital (weak acid — trapped in alkaline urine)
  • No specific antidote; no flumazenil benefit
Combination Overdose
Synergistic Lethality
  • Benzodiazepine + opioid: synergistic respiratory depression (boxed warning)
  • Address both agents: naloxone for opioid component, supportive care for benzodiazepine
  • Alcohol potentiates benzodiazepine and barbiturate CNS depression
  • Tricyclic antidepressants: QRS widening, arrhythmia — sodium bicarbonate treatment
Withdrawal Syndromes
Benzodiazepine Withdrawal
Potentially Fatal — Do Not Abruptly Stop
  • Anxiety, tremor, diaphoresis, insomnia, tachycardia within 24–72 hours
  • Seizures in physically dependent patients — potentially fatal
  • Short-acting agents (alprazolam, lorazepam): higher early seizure risk
  • Long-acting agents (diazepam): more gradual, self-tapering withdrawal
  • Treatment: gradual taper with long-acting benzodiazepine
Alcohol Withdrawal
CIWA-Ar Guided Treatment
  • Onset 6–24 hours after last drink; seizures peak at 24–48 hours
  • Delirium tremens (autonomic instability, confusion) at 48–96 hours if untreated
  • First-line: benzodiazepines dosed by CIWA-Ar score (symptom-triggered)
  • Long-acting preferred: diazepam or chlordiazepoxide (self-tapering)
  • Hepatic impairment: lorazepam or oxazepam (no active metabolites)
  • ICU alternative: phenobarbital infusion gaining evidence
Benzodiazepine Discontinuation Taper
Step 1
Switch to Long-Acting Agent
Convert to diazepam or clonazepam equivalent for smoother, more predictable taper
Step 2
Stabilize at New Agent
Confirm stable symptoms at equivalent dose before beginning dose reduction
Step 3
Reduce ~10% Every 1–2 Weeks
Slower for long-term users; hold if significant withdrawal symptoms emerge
Step 4
Final Low Doses
Slowest reduction at the end; transition support (CBT, adjuncts) maximizes success
Special Populations

Elderly: All benzodiazepines on Beers Criteria — increased fall risk, cognitive impairment, paradoxical agitation. Minimize use; if withdrawal needed, taper more slowly.

Flumazenil in dependent patients: Contraindicated. Precipitates withdrawal seizures that cannot be treated with benzodiazepines (binding site blocked). Only use in known non-dependent, short-term procedural sedation reversal.

Suggested References

Author / Organization Title Source
Katzung BG (ed) Basic and Clinical Pharmacology, 15th ed. Chapter 22: Sedative-Hypnotic Drugs McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 17: Hypnotics and Sedatives McGraw-Hill, 2023
Sun EC, Dixit A, Humphreys K, et al Association between concurrent use of prescription opioids and benzodiazepines and overdose BMJ. 2017;356:j760
Proudfoot AT, Krenzelok EP, Vale JA Position paper on urine alkalinization J Toxicol Clin Toxicol. 2004;42(1):1–26
Lader M Dependence and withdrawal: comparison of the benzodiazepines and selective serotonin reuptake inhibitors Addiction. 2012;107(5):909–910
Ashton H The diagnosis and management of benzodiazepine dependence Curr Opin Psychiatry. 2005;18(3):249–255
Schweizer E, Rickels K, Case WG, Greenblatt DJ Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy Arch Gen Psychiatry. 1991;48(5):448–452
Mayo-Smith MF Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline JAMA. 1997;278(2):144–151
Tidwell WP, Thomas TL, Pouliot JD, et al Treatment of alcohol withdrawal syndrome: phenobarbital versus CIWA-Ar protocol Am J Crit Care. 2018;27(6):454–460
Devlin JW, Skrobik Y, Gelinas C, et al Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU Crit Care Med. 2018;46(9):e825–e873
Mugunthan K, McGuire T, Glasziou P Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis Br J Gen Pract. 2011;61(590):e573–e578
American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc. 2023;71(7):2052–2081